ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Liposomal Doxorubicin Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-39C8806
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Liposomal Doxorubicin Market Outlook 2022
BUY CHAPTERS

Global Liposomal Doxorubicin Market Research Report 2024

Code: QYRE-Auto-39C8806
Report
February 2024
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
TEVA
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma

Liposomal Doxorubicin Market Size

The global Liposomal Doxorubicin market was valued at US$ 1272.6 million in 2023 and is anticipated to reach US$ 2152 million by 2030, witnessing a CAGR of 7.7% during the forecast period 2024-2030.

Liposomal Doxorubicin Market

Liposomal Doxorubicin Market

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.
Market competition is intense. Johnson & Johnson, Sun Pharmaceutical, CSPC, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 3 accounted for 60.41% market share.
This report aims to provide a comprehensive presentation of the global market for Liposomal Doxorubicin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Doxorubicin.

Report Scope

The Liposomal Doxorubicin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liposomal Doxorubicin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposomal Doxorubicin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Liposomal Doxorubicin Market Report

Report Metric Details
Report Name Liposomal Doxorubicin Market
Accounted market size in 2023 US$ 1272.6 million
Forecasted market size in 2030 US$ 2152 million
CAGR 7.7%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • 5 ml
  • 10 ml
  • 25 ml
Segment by Application
  • Breast Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Liposomal Doxorubicin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Liposomal Doxorubicin Market growing?

Ans: The Liposomal Doxorubicin Market witnessing a CAGR of 7.7% during the forecast period 2024-2030.

What is the Liposomal Doxorubicin Market size in 2030?

Ans: The Liposomal Doxorubicin Market size in 2030 will be US$ 2152 million.

Who are the main players in the Liposomal Doxorubicin Market report?

Ans: The main players in the Liposomal Doxorubicin Market are Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma

What are the Application segmentation covered in the Liposomal Doxorubicin Market report?

Ans: The Applications covered in the Liposomal Doxorubicin Market report are Breast Cancer, Liver Cancer, Kidney Cancer, Multiple Myeloma, Ovarian Cancer, Other

What are the Type segmentation covered in the Liposomal Doxorubicin Market report?

Ans: The Types covered in the Liposomal Doxorubicin Market report are 5 ml, 10 ml, 25 ml

1 Liposomal Doxorubicin Market Overview
1.1 Product Overview and Scope of Liposomal Doxorubicin
1.2 Liposomal Doxorubicin Segment by Type
1.2.1 Global Liposomal Doxorubicin Market Value Comparison by Type (2024-2030)
1.2.2 5 ml
1.2.3 10 ml
1.2.4 25 ml
1.3 Liposomal Doxorubicin Segment by Application
1.3.1 Global Liposomal Doxorubicin Market Value by Application: (2024-2030)
1.3.2 Breast Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Cancer
1.3.5 Multiple Myeloma
1.3.6 Ovarian Cancer
1.3.7 Other
1.4 Global Liposomal Doxorubicin Market Size Estimates and Forecasts
1.4.1 Global Liposomal Doxorubicin Revenue 2019-2030
1.4.2 Global Liposomal Doxorubicin Sales 2019-2030
1.4.3 Global Liposomal Doxorubicin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Liposomal Doxorubicin Market Competition by Manufacturers
2.1 Global Liposomal Doxorubicin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Liposomal Doxorubicin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Liposomal Doxorubicin Average Price by Manufacturers (2019-2024)
2.4 Global Liposomal Doxorubicin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Liposomal Doxorubicin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Liposomal Doxorubicin, Product Type & Application
2.7 Liposomal Doxorubicin Market Competitive Situation and Trends
2.7.1 Liposomal Doxorubicin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Liposomal Doxorubicin Players Market Share by Revenue
2.7.3 Global Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Liposomal Doxorubicin Retrospective Market Scenario by Region
3.1 Global Liposomal Doxorubicin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Liposomal Doxorubicin Global Liposomal Doxorubicin Sales by Region: 2019-2030
3.2.1 Global Liposomal Doxorubicin Sales by Region: 2019-2024
3.2.2 Global Liposomal Doxorubicin Sales by Region: 2025-2030
3.3 Global Liposomal Doxorubicin Global Liposomal Doxorubicin Revenue by Region: 2019-2030
3.3.1 Global Liposomal Doxorubicin Revenue by Region: 2019-2024
3.3.2 Global Liposomal Doxorubicin Revenue by Region: 2025-2030
3.4 North America Liposomal Doxorubicin Market Facts & Figures by Country
3.4.1 North America Liposomal Doxorubicin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Liposomal Doxorubicin Sales by Country (2019-2030)
3.4.3 North America Liposomal Doxorubicin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Liposomal Doxorubicin Market Facts & Figures by Country
3.5.1 Europe Liposomal Doxorubicin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Liposomal Doxorubicin Sales by Country (2019-2030)
3.5.3 Europe Liposomal Doxorubicin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Liposomal Doxorubicin Market Facts & Figures by Country
3.6.1 Asia Pacific Liposomal Doxorubicin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Liposomal Doxorubicin Sales by Country (2019-2030)
3.6.3 Asia Pacific Liposomal Doxorubicin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Liposomal Doxorubicin Market Facts & Figures by Country
3.7.1 Latin America Liposomal Doxorubicin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Liposomal Doxorubicin Sales by Country (2019-2030)
3.7.3 Latin America Liposomal Doxorubicin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Liposomal Doxorubicin Market Facts & Figures by Country
3.8.1 Middle East and Africa Liposomal Doxorubicin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Liposomal Doxorubicin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Liposomal Doxorubicin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Liposomal Doxorubicin Sales by Type (2019-2030)
4.1.1 Global Liposomal Doxorubicin Sales by Type (2019-2024)
4.1.2 Global Liposomal Doxorubicin Sales by Type (2025-2030)
4.1.3 Global Liposomal Doxorubicin Sales Market Share by Type (2019-2030)
4.2 Global Liposomal Doxorubicin Revenue by Type (2019-2030)
4.2.1 Global Liposomal Doxorubicin Revenue by Type (2019-2024)
4.2.2 Global Liposomal Doxorubicin Revenue by Type (2025-2030)
4.2.3 Global Liposomal Doxorubicin Revenue Market Share by Type (2019-2030)
4.3 Global Liposomal Doxorubicin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Liposomal Doxorubicin Sales by Application (2019-2030)
5.1.1 Global Liposomal Doxorubicin Sales by Application (2019-2024)
5.1.2 Global Liposomal Doxorubicin Sales by Application (2025-2030)
5.1.3 Global Liposomal Doxorubicin Sales Market Share by Application (2019-2030)
5.2 Global Liposomal Doxorubicin Revenue by Application (2019-2030)
5.2.1 Global Liposomal Doxorubicin Revenue by Application (2019-2024)
5.2.2 Global Liposomal Doxorubicin Revenue by Application (2025-2030)
5.2.3 Global Liposomal Doxorubicin Revenue Market Share by Application (2019-2030)
5.3 Global Liposomal Doxorubicin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Johnson & Johnson Liposomal Doxorubicin Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Sun Pharmaceutical
6.2.1 Sun Pharmaceutical Corporation Information
6.2.2 Sun Pharmaceutical Description and Business Overview
6.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Portfolio
6.2.5 Sun Pharmaceutical Recent Developments/Updates
6.3 CSPC
6.3.1 CSPC Corporation Information
6.3.2 CSPC Description and Business Overview
6.3.3 CSPC Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSPC Liposomal Doxorubicin Product Portfolio
6.3.5 CSPC Recent Developments/Updates
6.4 Kinyond
6.4.1 Kinyond Corporation Information
6.4.2 Kinyond Description and Business Overview
6.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kinyond Liposomal Doxorubicin Product Portfolio
6.4.5 Kinyond Recent Developments/Updates
6.5 Teva
6.5.1 Teva Corporation Information
6.5.2 Teva Description and Business Overview
6.5.3 Teva Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Teva Liposomal Doxorubicin Product Portfolio
6.5.5 Teva Recent Developments/Updates
6.6 Fudan-Zhangjiang
6.6.1 Fudan-Zhangjiang Corporation Information
6.6.2 Fudan-Zhangjiang Description and Business Overview
6.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Portfolio
6.6.5 Fudan-Zhangjiang Recent Developments/Updates
6.7 Zydus Cadila
6.6.1 Zydus Cadila Corporation Information
6.6.2 Zydus Cadila Description and Business Overview
6.6.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zydus Cadila Liposomal Doxorubicin Product Portfolio
6.7.5 Zydus Cadila Recent Developments/Updates
6.8 TTY Biopharma
6.8.1 TTY Biopharma Corporation Information
6.8.2 TTY Biopharma Description and Business Overview
6.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 TTY Biopharma Liposomal Doxorubicin Product Portfolio
6.8.5 TTY Biopharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Liposomal Doxorubicin Industry Chain Analysis
7.2 Liposomal Doxorubicin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Liposomal Doxorubicin Production Mode & Process
7.4 Liposomal Doxorubicin Sales and Marketing
7.4.1 Liposomal Doxorubicin Sales Channels
7.4.2 Liposomal Doxorubicin Distributors
7.5 Liposomal Doxorubicin Customers
8 Liposomal Doxorubicin Market Dynamics
8.1 Liposomal Doxorubicin Industry Trends
8.2 Liposomal Doxorubicin Market Drivers
8.3 Liposomal Doxorubicin Market Challenges
8.4 Liposomal Doxorubicin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
TEVA
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
List of Tables
    Table 1. Global Liposomal Doxorubicin Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Liposomal Doxorubicin Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Liposomal Doxorubicin Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Liposomal Doxorubicin Sales (K Unit) of Key Manufacturers (2019-2024)
    Table 5. Global Liposomal Doxorubicin Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Liposomal Doxorubicin Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Liposomal Doxorubicin Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Liposomal Doxorubicin Average Price (USD/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Liposomal Doxorubicin, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Liposomal Doxorubicin, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Liposomal Doxorubicin, Product Type & Application
    Table 12. Global Key Manufacturers of Liposomal Doxorubicin, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Liposomal Doxorubicin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Liposomal Doxorubicin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Liposomal Doxorubicin Sales by Region (2019-2024) & (K Unit)
    Table 18. Global Liposomal Doxorubicin Sales Market Share by Region (2019-2024)
    Table 19. Global Liposomal Doxorubicin Sales by Region (2025-2030) & (K Unit)
    Table 20. Global Liposomal Doxorubicin Sales Market Share by Region (2025-2030)
    Table 21. Global Liposomal Doxorubicin Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Liposomal Doxorubicin Revenue Market Share by Region (2019-2024)
    Table 23. Global Liposomal Doxorubicin Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Liposomal Doxorubicin Revenue Market Share by Region (2025-2030)
    Table 25. North America Liposomal Doxorubicin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Liposomal Doxorubicin Sales by Country (2019-2024) & (K Unit)
    Table 27. North America Liposomal Doxorubicin Sales by Country (2025-2030) & (K Unit)
    Table 28. North America Liposomal Doxorubicin Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Liposomal Doxorubicin Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Liposomal Doxorubicin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Liposomal Doxorubicin Sales by Country (2019-2024) & (K Unit)
    Table 32. Europe Liposomal Doxorubicin Sales by Country (2025-2030) & (K Unit)
    Table 33. Europe Liposomal Doxorubicin Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Liposomal Doxorubicin Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Liposomal Doxorubicin Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Liposomal Doxorubicin Sales by Region (2019-2024) & (K Unit)
    Table 37. Asia Pacific Liposomal Doxorubicin Sales by Region (2025-2030) & (K Unit)
    Table 38. Asia Pacific Liposomal Doxorubicin Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Liposomal Doxorubicin Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Liposomal Doxorubicin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Liposomal Doxorubicin Sales by Country (2019-2024) & (K Unit)
    Table 42. Latin America Liposomal Doxorubicin Sales by Country (2025-2030) & (K Unit)
    Table 43. Latin America Liposomal Doxorubicin Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Liposomal Doxorubicin Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Liposomal Doxorubicin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Liposomal Doxorubicin Sales by Country (2019-2024) & (K Unit)
    Table 47. Middle East & Africa Liposomal Doxorubicin Sales by Country (2025-2030) & (K Unit)
    Table 48. Middle East & Africa Liposomal Doxorubicin Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Liposomal Doxorubicin Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Liposomal Doxorubicin Sales (K Unit) by Type (2019-2024)
    Table 51. Global Liposomal Doxorubicin Sales (K Unit) by Type (2025-2030)
    Table 52. Global Liposomal Doxorubicin Sales Market Share by Type (2019-2024)
    Table 53. Global Liposomal Doxorubicin Sales Market Share by Type (2025-2030)
    Table 54. Global Liposomal Doxorubicin Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Liposomal Doxorubicin Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Liposomal Doxorubicin Revenue Market Share by Type (2019-2024)
    Table 57. Global Liposomal Doxorubicin Revenue Market Share by Type (2025-2030)
    Table 58. Global Liposomal Doxorubicin Price (USD/Unit) by Type (2019-2024)
    Table 59. Global Liposomal Doxorubicin Price (USD/Unit) by Type (2025-2030)
    Table 60. Global Liposomal Doxorubicin Sales (K Unit) by Application (2019-2024)
    Table 61. Global Liposomal Doxorubicin Sales (K Unit) by Application (2025-2030)
    Table 62. Global Liposomal Doxorubicin Sales Market Share by Application (2019-2024)
    Table 63. Global Liposomal Doxorubicin Sales Market Share by Application (2025-2030)
    Table 64. Global Liposomal Doxorubicin Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Liposomal Doxorubicin Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Liposomal Doxorubicin Revenue Market Share by Application (2019-2024)
    Table 67. Global Liposomal Doxorubicin Revenue Market Share by Application (2025-2030)
    Table 68. Global Liposomal Doxorubicin Price (USD/Unit) by Application (2019-2024)
    Table 69. Global Liposomal Doxorubicin Price (USD/Unit) by Application (2025-2030)
    Table 70. Johnson & Johnson Corporation Information
    Table 71. Johnson & Johnson Description and Business Overview
    Table 72. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 73. Johnson & Johnson Liposomal Doxorubicin Product
    Table 74. Johnson & Johnson Recent Developments/Updates
    Table 75. Sun Pharmaceutical Corporation Information
    Table 76. Sun Pharmaceutical Description and Business Overview
    Table 77. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 78. Sun Pharmaceutical Liposomal Doxorubicin Product
    Table 79. Sun Pharmaceutical Recent Developments/Updates
    Table 80. CSPC Corporation Information
    Table 81. CSPC Description and Business Overview
    Table 82. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 83. CSPC Liposomal Doxorubicin Product
    Table 84. CSPC Recent Developments/Updates
    Table 85. Kinyond Corporation Information
    Table 86. Kinyond Description and Business Overview
    Table 87. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 88. Kinyond Liposomal Doxorubicin Product
    Table 89. Kinyond Recent Developments/Updates
    Table 90. Teva Corporation Information
    Table 91. Teva Description and Business Overview
    Table 92. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 93. Teva Liposomal Doxorubicin Product
    Table 94. Teva Recent Developments/Updates
    Table 95. Fudan-Zhangjiang Corporation Information
    Table 96. Fudan-Zhangjiang Description and Business Overview
    Table 97. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 98. Fudan-Zhangjiang Liposomal Doxorubicin Product
    Table 99. Fudan-Zhangjiang Recent Developments/Updates
    Table 100. Zydus Cadila Corporation Information
    Table 101. Zydus Cadila Description and Business Overview
    Table 102. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 103. Zydus Cadila Liposomal Doxorubicin Product
    Table 104. Zydus Cadila Recent Developments/Updates
    Table 105. TTY Biopharma Corporation Information
    Table 106. TTY Biopharma Description and Business Overview
    Table 107. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 108. TTY Biopharma Liposomal Doxorubicin Product
    Table 109. TTY Biopharma Recent Developments/Updates
    Table 110. Key Raw Materials Lists
    Table 111. Raw Materials Key Suppliers Lists
    Table 112. Liposomal Doxorubicin Distributors List
    Table 113. Liposomal Doxorubicin Customers List
    Table 114. Liposomal Doxorubicin Market Trends
    Table 115. Liposomal Doxorubicin Market Drivers
    Table 116. Liposomal Doxorubicin Market Challenges
    Table 117. Liposomal Doxorubicin Market Restraints
    Table 118. Research Programs/Design for This Report
    Table 119. Key Data Information from Secondary Sources
    Table 120. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Liposomal Doxorubicin
    Figure 2. Global Liposomal Doxorubicin Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Liposomal Doxorubicin Market Share by Type in 2023 & 2030
    Figure 4. 5 ml Product Picture
    Figure 5. 10 ml Product Picture
    Figure 6. 25 ml Product Picture
    Figure 7. Global Liposomal Doxorubicin Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Liposomal Doxorubicin Market Share by Application in 2023 & 2030
    Figure 9. Breast Cancer
    Figure 10. Liver Cancer
    Figure 11. Kidney Cancer
    Figure 12. Multiple Myeloma
    Figure 13. Ovarian Cancer
    Figure 14. Other
    Figure 15. Global Liposomal Doxorubicin Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Liposomal Doxorubicin Market Size (2019-2030) & (US$ Million)
    Figure 17. Global Liposomal Doxorubicin Sales (2019-2030) & (K Unit)
    Figure 18. Global Liposomal Doxorubicin Average Price (USD/Unit) & (2019-2030)
    Figure 19. Liposomal Doxorubicin Report Years Considered
    Figure 20. Liposomal Doxorubicin Sales Share by Manufacturers in 2023
    Figure 21. Global Liposomal Doxorubicin Revenue Share by Manufacturers in 2023
    Figure 22. The Global 5 and 10 Largest Liposomal Doxorubicin Players: Market Share by Revenue in 2023
    Figure 23. Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 24. Global Liposomal Doxorubicin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 25. North America Liposomal Doxorubicin Sales Market Share by Country (2019-2030)
    Figure 26. North America Liposomal Doxorubicin Revenue Market Share by Country (2019-2030)
    Figure 27. U.S. Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. Canada Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. Europe Liposomal Doxorubicin Sales Market Share by Country (2019-2030)
    Figure 30. Europe Liposomal Doxorubicin Revenue Market Share by Country (2019-2030)
    Figure 31. Germany Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. France Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. U.K. Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Italy Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Russia Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. Asia Pacific Liposomal Doxorubicin Sales Market Share by Region (2019-2030)
    Figure 37. Asia Pacific Liposomal Doxorubicin Revenue Market Share by Region (2019-2030)
    Figure 38. China Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Japan Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. South Korea Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. India Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Australia Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Taiwan Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Indonesia Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Thailand Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Malaysia Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Philippines Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Latin America Liposomal Doxorubicin Sales Market Share by Country (2019-2030)
    Figure 49. Latin America Liposomal Doxorubicin Revenue Market Share by Country (2019-2030)
    Figure 50. Mexico Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Brazil Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. Argentina Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Middle East & Africa Liposomal Doxorubicin Sales Market Share by Country (2019-2030)
    Figure 54. Middle East & Africa Liposomal Doxorubicin Revenue Market Share by Country (2019-2030)
    Figure 55. Turkey Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 57. UAE Liposomal Doxorubicin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 58. Global Sales Market Share of Liposomal Doxorubicin by Type (2019-2030)
    Figure 59. Global Revenue Market Share of Liposomal Doxorubicin by Type (2019-2030)
    Figure 60. Global Liposomal Doxorubicin Price (USD/Unit) by Type (2019-2030)
    Figure 61. Global Sales Market Share of Liposomal Doxorubicin by Application (2019-2030)
    Figure 62. Global Revenue Market Share of Liposomal Doxorubicin by Application (2019-2030)
    Figure 63. Global Liposomal Doxorubicin Price (USD/Unit) by Application (2019-2030)
    Figure 64. Liposomal Doxorubicin Value Chain
    Figure 65. Liposomal Doxorubicin Production Process
    Figure 66. Channels of Distribution (Direct Vs Distribution)
    Figure 67. Distributors Profiles
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions